Lipase Variants for Pancreatic Enzyme Replacement Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved lipases with enhanced efficacy, activity, stability, and reduced allergenicity for pharmaceutical use, particularly in treating digestive disorders, pancreatic exocrine insufficiency, pancreatitis, cystic fibrosis, diabetes type I, and diabetes type II.
Innovation Solution
Development of lipases with specific amino acid substitutions, such as N33Q and T231R, which provide improved digestion performance, stability against proteases, and stability in bile salts, and are used in combination with protease and/or amylase for pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild type lipase from Humicola lanuginosa is used for pancreatic enzyme replacement therapy, then basic lipase activity is provided, but the enzyme shows insufficient stability against proteases and bile salts, and limited digestion performance in vivo
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid residues at specific positions in the lipase sequence (e.g., positions 33, 231, 233, and numerous other positions listed in the patent). These point mutations alter the enzyme's physical and chemical properties to enhance stability against proteolytic degradation and bile salt inhibition while maintaining or improving lipolytic activity, directly resolving the contradiction between stability and productivity
Solution Approach 2:
The patent creates composite enzymatic preparations by combining the modified lipase with proteases and amylases in pharmaceutical compositions. This composite approach allows the lipase variant to work synergistically with other digestive enzymes, enhancing overall digestion performance while the modified lipase provides the necessary stability to function effectively in the gastrointestinal environment
2Reliability
If existing lipase variants are developed for improved stability, then resistance to proteases and bile salts increases, but allergenicity may increase and pharmaceutical applicability remains unverified
Solution Approach 1:
The patent uses targeted amino acid substitutions to modify the lipase structure in ways that enhance stability while potentially reducing allergenicity. By changing specific residues that may be recognized by the immune system while maintaining catalytic function, the patent seeks to improve pharmaceutical suitability. The extensive list of acceptable substitutions at various positions provides multiple pathways to achieve stable, low-allergen variants
Solution Approach 2:
The patent develops lipase variants that can be produced recombinantly and used as single-use pharmaceutical formulations. The modified enzymes are designed to be sufficiently stable for therapeutic use but are formulated as disposable medical products, eliminating the need for long-term storage and reuse, thereby reducing the importance of extreme long-term stability while maintaining effectiveness during the therapeutic window
3Productivity
If lipase is used alone for treating digestive disorders, then specific lipolytic function is provided, but overall digestion performance is limited without combination with other enzymes
Solution Approach 1:
The patent creates composite pharmaceutical compositions containing the modified lipase combined with proteases and amylases. This multi-enzyme formulation approach enhances overall digestion performance by addressing multiple macronutrient types simultaneously. The modified lipase provides stable lipolytic activity while working synergistically with the other enzymes, and the formulations are designed to be manufacturable and clinically applicable despite the increased complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified lipases demonstrate improved in vivo and in vitro efficacy, enhanced stability, and reduced allergenicity, effectively addressing the limitations of existing lipases in treating various medical conditions.
Implementation Method 1
which lipase (a) has at least 50% identity to the sequence of amino acids 1 to 269 of SEQ ID NO: 2; (b) has lipase activity
Implementation Method 2
The modified lipases demonstrate improved in vivo and in vitro efficacy, enhanced stability
Implementation Method 3
stability against proteases
Implementation Method 4
stability in bile salts
Data Source
AI summary
The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.